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Abstract 
The present study describes the development and validation of a dissolution method for tadalafil, a 
Biopharmaceutical Classification System class II drug. 0.1N hydrochloric acid (HCl)+0.5% sodium lauryl sulphate (SLS), 
pH 4.5-acetate buffer+0.5% SLS and pH 6.8–phosphate buffer+0.5% SLS were tested as dissolution medium, and 
influences of apparatus, and rotation speed were evaluated. Samples were analyzed by UV spectrophotometric method at 
225 nm. The result also shows a better dissolution profile using pH 6.8–phosphate buffer + 0.5% SLS as medium and 
paddle as apparatus is a speed of 100 rpm. The conditions that allowed dissolution determination were USP type II 
apparatus at 100 rpm, containing 900 mL of pH 6.8–phosphate buffer+0.5% SLS as dissolution medium, with analysis at 
wavelength of 225 nm. Samples were analyzed by UV spectrophotometric method and validated as per ICH guidelines, 
showing specificity, linearity, precision and accuracy. 
Keywords: Dissolution, BCS Class IV drug, Validation. 
 
1. Introduction 
Development of dissolution tests for immediate 
release oral dosage forms such as tablets and coated tablets 
has become an important tool for pharmaceutical 
companies in order to assess lot-to-lot quality of a drug 
product; to guide development of new drug formulations 
and ensure consistent product quality and performance after 
certain changes such as alterations in formulation and the 
manufacturing process [1–2]. Besides, when is possible an 
in vitro/in vivo correlation, dissolution can be used as a test 
in order to predict the drug bioavailability, thus, being able 
to determinate drug bioequivalence [3–5]. 
 The development of an analytical method involves 
an evaluation process to estimate their efficiency on 
laboratory routine. As long the method are developed, in 
order to scientifically prove their efficiency, it is essential to 
carry out the validation of the developed method. 
Validation must guarantee, by experimental studies, that the 
method meets the requirements of the analytical 
applications, ensuring results reliability. Thus, validation is 
intended to demonstrate that the method is suitable for the 
intended purpose. This is done by demonstrating parameters 
such as specificity, linearity, accuracy and precision 
suitable for analysis [6–13]. 
Developing an appropriate in vitro dissolution test 
for drug products with lower water solubility has been a 
challenge for pharmacists. Those drugs, classified into 
classes II or IV by the Biopharmaceutical Classification 
System (BCS), depending on their apparent permeability. 
Drug release is usually the rate-limiting step for oral 
absorption of these substances
14
. 
Tadalafil, a drug used on erectile dysfunction 
treatment, is commercially available on Brazil by the brand 
name Cialis
®
 as coated tablets with a labeled amount of 20 
mg. Tadalafil, a water insoluble drug, is classified as BCS 
Class II drug and shows a LogP: 1.42 and a pKa: 0.85 
[10,14–17]. Low water solubility drugs do not show a good 
dissolution on water, even at the pH physiological range, 
and may require the use of surfactants [18]. Surfactants act 
by reducing the interfacial tension between the drug and the 
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solvent, increasing drug dissolution. One of the action 
mechanisms is related to the particle wettability, where the 
surfactant favors the contact between the drug particle and 
the surrounding liquid. 
As a dissolution methodology for tadalafil tablets 
is described at USP 39 – NF 34 [10], that method use 
HPLC in order to quantify the drug. As UV 
spectrophotometry is a simpler method, and also faster than 
HPLC,this paper aims to describe the development and 
validation of a dissolution test for tadalafil coated tablets by 
an ultraviolet method. 
 
2. Materials & Methods 
2.1 Materials and equipment  
All chemicals and reagents were of analytical 
reagent grade. Pharmaceutical company Prati–Donaduzzi 
(Toledo, Brazil), kindly donated tadalafil reference 
substance (99.83 %). The reference drug product (Cialis
®
), 
labelled as containing 20 mg of tadalafil and the following 
excipients (croscarmelose sodium, hydroxypropyl cellulose, 
hypromellose, magnesium stearate, microcrystalline 
cellulose, monohydrate lactose, sodium laurylsulphate, 
titanium dioxide, triacetin and yellow iron oxide) were 
obtained commercially. 
 Equipment and instruments used in the present 
study were analytical scale (Gehaka, AG–200 model), 
dissolution test apparatus (Nova Ética, 301-6 AUT model), 
ultrasonic bath (Químis, Q355D model) and UV 
spectrophotometer (UV-1600 Pró–Análise). 
2.2 Methodology  
2.2.1 Maximum wavelength absorption determination 
 It was prepared three different standard 
solutionswith 22.22 µg/mL of tadalafil in the following 
medium: 0.1N hydrochloric acid (HCl) + 0.5 % sodium 
lauryl sulphate (SLS), pH 4.5-acetate buffer + 0.5 % SLS 
and pH 6.8–phosphate buffer + 0.5 % SLS. The samples 
were submitted to an UV scan spectrum between 800 to 200 
nm in order to determinate tadalafil maximum wavelength 
absorption. 
2.2.2 Dissolution test conditions 
Dissolution testing of tablets was performed with 
the reference drug product (Cialis
®
 20 mg) in accordance 
with the USP to define the dissolution test conditions. 
Initially, this was performed using paddles (USP apparatus 
II) at a stirring speed of 50 rpm and 900 mL of the 
following dissolution media, pre-heated to 37 °C ± 0.5°C: 
0.1N HCl + 0.5 % SLS; pH 4.5–acetate buffer + 0.5 % SLS 
and pH 6.8–phosphate buffer + 0.5 % SLS. Manual 
sampling aliquots of 20.0 mL were withdrawn at 5, 10, 15, 
30 and 45 minutes, filtered in a Millex
®
 filter and analyzed 
on a UV/VIS Spectrophotometer (225 nm). There was no 
medium replacement after the sampling. The tadalafil 
standard solution was prepared in order to obtain a final 
concentration of 0.0222 mg/mL. 
After these preliminary studies, tests to 
determinate the apparatus (paddles and baskets) and 
rotation speed (50 and 100 rpm for paddles; 75 and 100 rpm 
for baskets) were performed using as dissolution medium 
pH 6.8–phosphate buffer + 0.5 % SLS maintained at 37 ± 
0.5ºC.Also, sampling aliquots of 20.0 mL were withdrawn 
manually at 5, 10, 15, 30 and 45 minutes, filtered(Millex
®
 
filter) and analyzed on a UV/VIS Spectrophotometer (225 
nm), together with a standard solution of tadalafil in 22.22 
µg/mL final concentration. 
2.2.3 Validation 
In order to demonstrate the method’s suitability for 
use as a dissolution test, it was validated based on 
specificity, linearity, precision and accuracy parameters 
[6,19]. 
2.2.3.1 Specificity 
Placebo samples of Cialis
®
 (a mix of the excipients 
from tadalafil-coated tablets) were prepared empirically in 
their usual compositions, according to literature [20–21]. 
The placebo samples were transferred to different vessels 
(n=6) with 900 mL of pH 6.8–phosphate buffer + 0.5 % 
SLS as dissolution medium at 37 °C ± 0.5 °C and stirred for 
1 h at 100 rpm using a paddle (USP apparatus II). Aliquots 
of these solutions were filtered through a Millex
®
 filter and 
analyzed by the UV method (225 nm). 
2.2.3.2 Linearity 
A stock solution was prepared containing 222.22 
µg/mL of tadalafil using pH 6.8–phosphate buffer + 0.5 % 
SLS as solvent. Aliquots of this solution were transferred to 
volumetric flasks to obtain final concentrations of 4.44; 
8.89; 13.33; 17.78; 22.22; and 26.67 µg/mL. Each solution 
was prepared in triplicate. The linearity was evaluated by 
linear regression analysis, which was calculated by the least 
squares regression method and analysis of variance 
(ANOVA). 
2.2.3.3 Precision  
The evaluation of intermediate precision (inter-day 
precision) of the dissolution test was performed on three 
different days. The repeatability was evaluated on the same 
day for intra-day precision in six vessels used for the 
dissolution test. The relative standard deviation (RSD) from 
the results was calculated. 
2.2.3.4 Accuracy  
Accuracy was determinate by the recovery 
percentage of a known amount of tadalafil reference 
substance added to a placebo solution. A recovery study 
was conducted by adding known amounts of the tadalafil 
stock solution to the dissolution vessels containing the 
placebo solution (50, 100 and 150 %) of the nominal assay 
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(20 mg). Each concentration was prepared in triplicate and 
analyzed by the UV method at 225 nm. 
 
3.Results and Discussion 
3.1. Dissolution method development 
As tadalafil is classified as a Class II drug (low 
solubility and high permeability) in Biopharmaceutical 
Classification System (BCS), it is justified the use of 
surfactants in order to improve drug solubility. Sodium 
lauryl sulphate (SLS), which increased drug dissolution by 
decreasing the interfacial tension between drug and solvent, 
was selected as surfactant to be added in an amount of 0.50 
% in all the dissolution mediums tested [22]. 
The first test was to determine in which 
wavelength tadalafil showed UV absorption. The results of 
the UV scan spectrum between 800 – 200 nm showed 
demonstrated that tadalafil showed a maximum absorption 
at 225 nm (Figure 1). 
 
 
Figure 1: Tadalafil standard solution UV scan spectrum 
 
The dissolution profiles in media at physiological 
pH range (1.2 to 6.8) need to be evaluated for immediate 
release drugs. Thus, dissolution tests on 0.1 N HCl, pH 4.5-
acetate buffer and pH 6.8–phosphate buffer as dissolution 
medium, all added with 0.50 % SLS allowed evaluate 
which medium showed better discriminative dissolution 
profile. The results (Figure 2) showed that there was no 
total tadalafil dissolution on 0.1 N HCl + 0.5 % SLS, where 
the final drug dissolution was 74.77 %. Similar results were 
obtained when pH 4.5-acetate buffer + 0.5 % SLS, when 
the final drug dissolution was close to 90 % (89.51 %). 
 
Figure 2: Dissolution profile of tadalafil tablets in 0.1 N HCl + 0.50 % SLS, pH 4.5-acetate buffer + 0.50 % SLS and 
pH 6.8-phosphate buffer + 0.50 % SLS. 
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The dissolution medium which showed complete 
tadalafil dissolution was pH 6.8–phosphate buffer + 0.5 % 
SLS, where the final drug release was 98.59 %. Also, the 
dissolution profile at five points (5, 10, 15, 30 and 45 
minutes) showed that tadalafil dissolved more than 85% in 
15 minutes (Figure 2). As tadalafil must be ready to act in 
the men body around 30 minutes after the drug intake [14], 
a rapidly drug dissolution is required for immediate-release 
dosage forms [10,21].  
Therefore, the choice of pH 6.8-phosphate buffer + 
0.5 % SLS as dissolution medium was due to its good 
solubility, accessibility, low cost and the fact that it is a 
typical dissolution medium [23–24]. 
After the dissolution medium was determinate, 
apparatus type and speed were tested. The most common 
dissolution conditions are basket (USP apparatus I) at 50 or 
100 rpm as rotation speed and paddles (USP apparatus II) in 
a rotation of 75 or 100 rpm [13]. The tadalafil dissolution 
(Figure 3) showed a better result when paddles at 50 rpm 
are used, when a drug release of 99.93 % were obtained. 
The other apparatus conditions, paddles at 100 rpm was not 
able to provide a more discriminated dissolution profile, 
since shows more than one point with more than 90 % of 
drug dissolution, and baskets at 75 rpm and at 100 rpm 
didn’t provide total drug dissolution, showing drug final 
dissolution of 92.30 % and 94.71 %, respectively. 
 
 
Figure 3: Dissolution profile of tadalafil tablets in paddles (50 and 100 rpm) and baskets (75 and 100 rpm) using pH 
6.8–phosphate buffer + 0.50 % SLS as dissolution medium. 
 
Based on the results, is possible to determinate that 
a good dissolution method for tadalafil-coated tablets is 
using 900 mL pH 6.8–phosphate buffer + 0.5 % SLS as 
dissolution medium with paddles at 50 rpm, samples 
withdraw at 5, 10, 15, 30 and 45 minutes, filtered and 
analyzed at spectrophotometer at 225 nm. 
3.2. Dissolution method validation 
 Validation of an analytical method is the processes 
that establish that performance characteristics of the 
procedure meet the requirements for the intended analytical 
applications [10]. In order for the developed dissolution 
method meets the requirements of the analytical 
applications, ensuring results reliability, it should be 
validated.  
The determinate the specificity, which is the ability 
to assess unequivocally the substance in the presence of 
components that may be expected to be present [26], 
analysis of a tadalafil placebo solutions showed that the UV 
method suffer no interference from the formulation of the 
tablet evaluated, demonstrating to be specific (Figure 1). 
Since there was no interference from the excipients with the 
selected wavelength (225 nm), UV can be used in order to 
quantify tadalafil. Generally, UV is usually used in quality 
control of pharmaceuticals because most of drugs absorbed 
energy in UV region, and is a method, which does not 
require a complex or expensive equipment, and there is no 
need for toxic solvents [27]. In addition, by using UV 
method, results can be obtained faster, analysis is simpler 
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and fewer solvents are used, making this valuable in routine 
analysis [28–29]. 
In order to assess linearity, three calibration curves 
of tadalafil were constructing and plotted graphically as 
concentration (µg/mL) versus absorbance. The results 
(Figure 4) showed a good correlation coefficient (R
2
: 
0.9993) in the studied concentration range (4.44 – 26.67 
µg/mL
–1
). The representative linear equation was y = 
0.0354x + 0.1331 and the data were validated by means of 
the analysis of variance (ANOVA), which demonstrated 
significant linear regression and no significant linearity 
deviation (p < 0.01) [10,25]. According to the results, 
linearity was proved because an appropriate linear 
correlation was found since the obtained correlation 
coefficients showed values higher that 0.99 [6–7].  
 
Figure 4: Linearity curve of tadalafil standard solution in pH 6.8–phosphate buffer + 0.50 % SLS 
 
Precision of the method was determined by 
measuring the repeatability and intermediate precision. The 
results showed a low relative standard deviation (RSD) 
ranging from 0.49 to 0.45 % for intra-day precision and 
0.94 % for inter-day precision. As RSD values were lower 
than 2%, the results indicated the good precision of this 
method [6–7]. 
The accuracy of the analytical procedure, which is 
the accordance between the accepted value and the value 
found, was demonstrated by the recovery of known 
amounts of tadalafil in the dissolution vessels. In the 
present study, three concentrations were evaluated (11.11, 
22.22 and 33.33µg/mL) and each concentration was 
measured three times. The recovery percentage found 
ranged from 99.25 to 100.70 %, indicating method’s 
accuracy. As the measured recovery is typically 95–105%, 
the results indicated good accuracy of the method. The 
recovery percentage was calculated in triplicate and the 
mean value was considered. 
 
4. Conclusions 
 A discriminative dissolution method to evaluate 
tadalafil-coated tablets by ultraviolet spectrophotometry 
was success developed and demonstrated to be an easy, fast 
and simple method. The conditions allowing dissolution 
determination were 900 mL of pH 6.8–phosphate buffer 
with 0.50 % of SLS as dissolution medium, using USP type 
II apparatus (paddles) at 50 rpm and analysis by 
spectrophotometric detection in a wavelength of 225 nm. 
The spectrophotometric method was validated and showed 
to be specific, linear, precise and accurate.  
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